{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:35:16Z","timestamp":1788240916362,"version":"build-2803163510"},"reference-count":40,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Pan-European Real Life (PEARL) Phase 4 study evaluated real-world effectiveness and safety of fremanezumab for episodic migraine (EM) and chronic migraine (CM) prevention. This post-hoc analysis evaluated the effectiveness of fremanezumab in participants with three or more non-migraine-specific preventive treatment failures, including onabotulinumtoxinA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Baseline daily headache diary data were compared with diary data following fremanezumab initiation. Primary endpoint: proportion of participants with \u226550% reduction in monthly migraine days (MMD) during the six months after fremanezumab initiation. Secondary endpoints included mean change from baseline in MMD at Months 1\u201312 and health-related quality of life. Safety was assessed through adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 451 participants, 398 with three or more previous preventive treatment failures were included in the effectiveness analyses (EM, 40.2%; CM, 59.8%). Of the 290 participants with data available, the 50% responder rate was 53.8% (EM, 67.0%; CM, 46.5%) during the six months after fremanezumab initiation. The safety profile was consistent with previous findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This post-hoc analysis supports the effectiveness and safety of fremanezumab for migraine prevention in patients with three or more prior preventive treatment failures. These findings are consistent with those from a randomized controlled trial (RCT) in a similar population, illustrating the transferability of RCT data to real-world clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>encepp.eu: EUPAS35111.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024251395029","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T14:59:56Z","timestamp":1766501996000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Addressing unmet needs in migraine: Real-world fremanezumab effectiveness in participants of the PEARL study with at least three prior preventive treatment failures"],"prefix":"10.1177","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0951-5804","authenticated-orcid":false,"given":"Messoud","family":"Ashina","sequence":"first","affiliation":[{"name":"Department of Neurology, Danish Headache Center, Copenhagen University Hospital \u2013 Rigshospitalet, Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-2113","authenticated-orcid":false,"given":"Cristina","family":"Tassorelli","sequence":"additional","affiliation":[{"name":"Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy"},{"name":"IRCCS Mondino Foundation, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar","family":"Kokturk","sequence":"additional","affiliation":[{"name":"TEVA Pharmaceuticals Europe B.V., Haarlem, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Akcicek","sequence":"additional","affiliation":[{"name":"TEVA Pharmaceuticals Europe B.V., Haarlem, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0796-4702","authenticated-orcid":false,"given":"Patricia","family":"Pozo-Rosich","sequence":"additional","affiliation":[{"name":"Headache Unit, Neurology Department, Vall d\u2019Hebron University Hospital and Headache Research Group, Vall d\u2019Hebron Research Institute, Universitat Autonoma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32342-4"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.12055"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416678382"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2014.20.1.22"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-021-00331-3"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01130-5"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01655-5"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01335-2"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.4853"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709038"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01173-8"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.13997"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010600"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.13994"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31946-4"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01431-x"},{"key":"e_1_3_3_18_2","first-page":"927","article-title":"Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world","volume":"95","author":"Caronna E","year":"2024","unstructured":"Caronna E, Gallardo VJ, Egeo G, et al. Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world. J Neurol Neurosurg Psychiatry 2024; 95: 927\u2013937.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-023-01183-6"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph14070700"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00893-y"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15740"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01561-w"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01396-x"},{"key":"e_1_3_3_25_2","first-page":"45","article-title":"Efficacy of fremanezumab in resistant and refractory chronic migraine patients: real-world data from the Hull Migraine Clinic, UK","volume":"5","author":"Cheng F","year":"2022","unstructured":"Cheng F, Wu Q, Hussain M, et al. Efficacy of fremanezumab in resistant and refractory chronic migraine patients: real-world data from the Hull Migraine Clinic, UK. Adv Neurol Neurosci 2022; 5: 45\u201367.","journal-title":"Adv Neurol Neurosci"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231214987"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.2217\/pmt-2021-0015"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1915327"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2009.08.019"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2008.01555.x"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0946-z"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.18058"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.93"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01111-8"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416636055"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01433-9"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01127-0"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2377347"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32160-7"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0951"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024251395029","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024251395029","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024251395029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:46:41Z","timestamp":1777387601000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024251395029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1177\/03331024251395029"],"URL":"https:\/\/doi.org\/10.1177\/03331024251395029","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"article-number":"03331024251395029"}}